Trial · NCT07247656
The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .
NCT07247656, Phase 4, Completed, Bahria University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients . Trials, record NCT07247656. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07247656
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .
- NCT number
- NCT07247656
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 200 participants, actual
- Lead sponsor
- Bahria University
- Conditions
- Diabete Mellitus
- Interventions
- (Empagliflozin 10 mg+ Tab Linagliptin 5mg), Tab Empagliflozin 10 mg + Tab Metformin 500 mg
- First posted
- 2025-11-25
- Last updated
- 2025-11-25
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall improvement in Fasting Blood Glucose | 12 weeks | Fasting Blood glucose ( mg / dl ) was measured using Glucometer |
| Primary | Overall change in Body Mass Index ( kg/m2) | 12 weeks | Body Mass Index ( kg/m2) was recorded using weighing balance and measuring tape . |
| Primary | Overall improvement in Random Blood Glucose | 12 weeks | Random Blood Glucose was measured in mg/dl using Glucometer |
| Primary | Over all improvement in Glycated Hemoglobin ( HbA1c) | 12 weeks | Blood sample was taken to assess HbA1c |
| Primary | Overall change in Waist to Hip Ratio | 12 weeks | Measuring tape was used to measure |
| Primary | Overall change in Waist Circumference | 12 weeks | Was measured in inches using measuring tape |
| Secondary | To observe adverse effects in treatment groups | 12 weeks | 1. To evaluate any incidence of Hypoglycemic events during study period 2. To evaluate any incidence of Glycosuria during study period |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07247656
GET https://conductscience.org/api/trials/v1/NCT07247656/registered